NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES

THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.

  • Dr. Fabrice NAVARRO, New Deal Project Coordinator

THE PROJECT GOALS

The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.

Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.

Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut

Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.

THE PROJECT NEWS

July New Deal Reads

July 10th, 2020|

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. Yang C. and Merlin D. 2019. Int [...]

June New Deal Reads

June 16th, 2020|

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Amoroso C. et al. 2020. Cells, [...]

May New Deal Reads

May 26th, 2020|

Covid-19 and immunomodulation in IBD. Neurath MF, 2020. Gut; 0:1–8. The world is currently facing a coronavirus pandemic [...]

More news

THE PROJECT PARTNERS

From 2017 to 2018